Zibb.com: Exxon Mobil Corporation (Industry News & Blogs)

industrialinfo.com - Exxon Mobil's Acajutla Refinery Undergoes Pl...

Tue, 22 Sep 2009 00:00:00 GMT

This article is available for Premium Members only. Subscribe Now! All Fields are Required...

Medivation starts Phase III study for Huntington's (at MarketWatc...

Thu, 30 Jul 2009 13:06:36 GMT

BOSTON (MarketWatch) -- Partners Medivation Inc. and Pfizer Inc. said Thursday that they have started Phase III testing of their compound dimebon for the treatment of Huntington's disease. The trial will test to see if dimebon can help improve thinking and memory in patients stricken with the

GlaxoSmithKline's New Ally For Alli (at CNBC)

Fri, 20 Mar 2009 15:28:11 GMT

Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.

Sequenom Misses, but Who Cares?

Fri, 31 Oct 2008 02:11:22 GMT

Trader Mark submits:Near term results for Sequenom (SQNM) are really a moot point as we're looking to mid 2009

Novartis Moves to the Next Stage (at BusinessWeek)

Mon, 20 Oct 2008 19:42:38 GMT

After a 32% jump in profits, the Swiss drugmaker will shuffle managers and cut 550 U.S. sales jobs as it pursues growth with a new marketing strategy.

Verizon reaches agreement with unions

Mon, 11 Aug 2008 14:00:10 GMT

Under the terms of the new deal, the Communications Workers of America and the International Brotherhood of Electrical Workers, which represent 65,000 Verizon (NYSE:VZ) employees, will received a 10.5 percent pay increase and will change to a defined contribution plan.

Genentech Lifted by Avastin Sales

Tue, 15 Jul 2008 03:54:42 GMT

Genentech reported higher-than-expected quarterly sales of its most important product, the cancer drug Avastin, and raised its earnings outlook for the year.

Exxon Mobil Earnings Fall 66% To $4.1 Billion

ExxonMobil (XOM) reported a 66% drop in earnings during its second quarter due to fluctuating oil prices and well-stocked oil reserves that led to a sluggish demand for crude. In order to keep with demand, production at Exxon dropped by 3% in the quarter.

ISA | Alaska says no to Exxon's North Slope gas plan

It will most likely end up in court, as Alaska rejected Exxon Mobil Corp’s plan for the giant Point Thomson natural gas field on the North Slope.

Pfizer: Seeking Alpha in Pharma

Mon, 22 Sep 2008 19:24:08 GMT

Shiv Kapoor submits: PMy view is that there is a strong case for major Pharma, even if its science is slow in delivery. The valuations and yield is great and the growth potential enormous - the twin

When It Rains Risk, It Pours (at CNBC)

Wed, 27 Aug 2008 15:30:15 GMT

Within a 12-hour period five biopharma companies revealed negative drug news that is sending their stocks lower -- in the case of Amylin Pharmaceuticals and Cell Genesys, much lower. After the closing bell Tuesday, Bristol-Myers Squibb and Pfizer had an announcement to make...

Biotech Stocks: Alkermes, King lead drug stocks higher (at Market...

Fri, 08 Aug 2008 14:32:00 GMT

Drug stocks move into positive territory as shares of Alkermes shoot up after it raises its fiscal 2009 financial outlook.

NEWS: Roche's Big Hurdle with Genentech (at BusinessWeek)

Mon, 28 Jul 2008 16:56:32 GMT

Like others that have snapped up biotechs, its challenge will be to hang on to the brainpower.

Biopharma Analyst Musical Chairs (at CNBC)

Wed, 02 Jul 2008 14:41:55 GMT

In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.

Steve Forbes: the Folly of Forcing Exxon to "Go Green"

Thu, 05 Jun 2008 13:50:31 GMT

The Rockefellers have decided to pressure ExxonMobil's (NYSE:XOM) (Irving, Texas) board of directors to make them more responsive to ...

A Contrarian Look at Pfizer

Mon, 19 May 2008 12:37:11 GMT

Stuart J. Shaw submits:Informed opinion almost always advocates the popular course, so you must steel yourself to stand apart. To be a contrarian is to be an outsider â€“ until youâ€™re proven right. (David Dreman,

Amgen gains on osteoporosis study; quarterly results on deck (at ...

Mon, 28 Jul 2008 15:22:00 GMT

Shares of Amgen rally, playing off positive trial data on its osteoporosis drug candidate, as investors await second-quarter financial results for the biotech bellwether due out after Monday's close.

Biotech Stocks: Roche bid for Genentech stokes biotech stocks (at...

Mon, 21 Jul 2008 14:22:00 GMT

Biotech stocks get a nice boost early from news that Swiss drugmaker Roche plans to buy the remaining 44% of Genentech Inc. that it doesn't already own for $43.7 billion.

Amgen and JNJ's Anemia Drug Showdown

Wed, 12 Mar 2008 21:07:37 GMT

Mike Huckman submits: Ahead of the big Food and Drug Administration Advisory Committee meeting tomorrow, Amgen held a quick conference call with some reporters this afternoon. The outside panel of experts will be

Affymetrix Q4 2007 Earnings Call Transcript

Mon, 04 Feb 2008 16:38:12 GMT

Complete Story

Johnson Johnson Q4 2007 Earnings Call Transcript

Tue, 22 Jan 2008 20:48:28 GMT

Complete Story

ViroPharma Incorporated: More FDA Incompetence

Fri, 18 Jan 2008 08:38:43 GMT

Theodore Cohen submits:Hard on the heels of the corrupted approval process associated with Dendreonâ€™s (DNDN) Provenge comes evidence of still more incompetence at the Federal agency responsible for this nationâ€™s healthcare.

Two Great Gifts: Elbit Medical Imaging and Jacada

Sun, 13 Jan 2008 16:29:42 GMT

Aaron Katsman submits: With gold prices surging, I canâ€™t afford to by my

What's Next For Medarex?

Wed, 12 Dec 2007 11:24:22 GMT

Christopher Ssembonge submits:On Monday evening, Medarex (MEDX) announced theresults of one of the three completed clinical trials being carried outon one

Elan On Eight-Eight-Oh-Eight, Etc. (at CNBC)

Fri, 08 Aug 2008 14:55:54 GMT

The Elanians have been pretty quiet in the wake of last week's bad news. and the stock getting about a two-thirds haircut. And I don't mean to rub salt in the wound.